litlas
ログインアカウント作成

Se Hoon Park

2004–2025 年に発表

別表記
Se-Hoon Park
153
論文数
23,554
被引用数
66
h 指数
130
i10 指数

被引用数

Se Hoon Park の年別被引用数2001 年: 被引用 2 件2004 年: 被引用 1 件2005 年: 被引用 10 件2006 年: 被引用 20 件2007 年: 被引用 10 件2008 年: 被引用 6 件2009 年: 被引用 8 件2010 年: 被引用 9 件2011 年: 被引用 12 件2012 年: 被引用 25 件2013 年: 被引用 39 件2014 年: 被引用 50 件2015 年: 被引用 70 件2016 年: 被引用 73 件2017 年: 被引用 84 件2018 年: 被引用 111 件2019 年: 被引用 545 件2020 年: 被引用 919 件2021 年: 被引用 1,212 件2022 年: 被引用 1,123 件2023 年: 被引用 941 件2024 年: 被引用 1,748 件2025 年: 被引用 913 件2026 年: 被引用 30 件2002〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,160 件、この内訳の 20%中国: 引用元論文 1,822 件、この内訳の 16.8%イタリア: 引用元論文 669 件、この内訳の 6.2%イギリス: 引用元論文 634 件、この内訳の 5.9%日本: 引用元論文 545 件、この内訳の 5%ドイツ: 引用元論文 487 件、この内訳の 4.5%韓国: 引用元論文 482 件、この内訳の 4.5%フランス: 引用元論文 445 件、この内訳の 4.1%スペイン: 引用元論文 381 件、この内訳の 3.5%カナダ: 引用元論文 319 件、この内訳の 2.9%オランダ: 引用元論文 254 件、この内訳の 2.3%オーストラリア: 引用元論文 204 件、この内訳の 1.9%
0%20%その他 22.4%

機関

分野

  • Medicine71.7%
  • Biochemistry, Genetics and Molecular Biology21.2%
  • Immunology and Microbiology3.3%
  • Engineering1%
  • Neuroscience0.8%
  • Computer Science0.7%
  • その他1.3%

トピック

  • Cancer Immunotherapy and Biomarkers9.7%
  • Bladder and Urothelial Cancer Treatments5.4%
  • Gastric Cancer Management and Outcomes5.3%
  • Ferroptosis and cancer prognosis3.5%
  • Cancer Genomics and Diagnostics3%
  • Renal cell carcinoma treatment2.5%
  • その他70.6%

共著者

全論文

検索で開く
  1. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    著者: Seung Tae Kim, Răzvan Cristescu, Adam J. Bass, Kyoung‐Mee Kim, Justin I. Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mi-Jin Lee, Sujin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Hyuk Lee, Min Gew Choi, AmirAli Talasaz, Peter Kang, Jonathan D. Cheng, Andrey Loboda, Jeeyun Lee, Won Ki Kang - Nature Medicine 2018 被引用: 1,717

  2. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    著者: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden - New England Journal of Medicine 2024 被引用: 914

  3. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    著者: Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas - New England Journal of Medicine 2020 被引用: 1,479

  4. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

    著者: Răzvan Cristescu, Jeeyun Lee, Michael Nebozhyn, Kyoung‐Mee Kim, Jason C. Ting, Swee Seong Wong, Jiangang Liu, Yong Yue, Jian Wang, Kun Yu, Xiang S. Ye, In‐Gu Do, X. Shawn Liu, Lara Gong, Jake Fu, Jason Jin, Min Gew Choi, Tae Sung Sohn, Joon Ho Lee, Jae Moon Bae, Seung Tae Kim, Se Hoon Park, Insuk Sohn, Sin‐Ho Jung, Patrick Tan, Ronghua Chen, James C.H. Hardwick, Won Ki Kang, Mark Ayers, Dai Hongyue, Christoph Reinhard, Andrey Loboda, Sung Kim, Amit Aggarwal, Sung Kim, Amit Aggarwal - Nature Medicine 2015 被引用: 2,244

  5. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

    著者: Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, Michael Schenker, Begoña P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebrét, Shahrokh F. Shariat, Se Hoon Park, Dingwei Ye, Mads Agerbæk, Deborah Enting, Ray McDermott, Pablo Gajate, Avivit Peer, Matthew I. Milowsky, А. К. Носов, João Neif Antonio, Krzysztof Tupikowski, Laurence Toms, Bruce S. Fischer, Anila Qureshi, Sandra Collette, Keziban Ünsal-Kaçmaz, Edward Broughton, Dimitrios Zardavas, Henry Koon, Matthew D. Galsky - New England Journal of Medicine 2021 被引用: 1,031

  6. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

    著者: Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Bob Zhong, Kim Stuyckens, Ademi Santiago-Walker, Peter De Porre, Anne O’Hagan, Anjali Narayan Avadhani, Arlene O. Siefker‐Radtke - New England Journal of Medicine 2019 被引用: 1,365

  7. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

    著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Yen‐Hwa Chang, Jaroslav Hájek, Stefan N. Symeonides, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Howard Gurney, Christine Chevreau, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, John M. Burke, Gurjyot K. Doshi, Delphine Topart, Stéphane Oudard, Hans J. Hammers, Hiroshi Kitamura, Jens Bedke, Rodolfo F. Perini, Pingye Zhang, Kentaro Imai, Jaqueline Willemann-Rogerio, David I. Quinn, Thomas Powles - New England Journal of Medicine 2021 被引用: 746

  8. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

    著者: Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, Jeffrey C. Goh, Kristiina Ojamaa, Christopher Hoimes, Ulka N. Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend, Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein, Johann S. de Bono - Journal of Clinical Oncology 2019 被引用: 706

  9. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

    著者: Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias, Ian D. Davis, Maria De Santis, Eiji Kikuchi, Xavier García del Muro, Ugo De Giorgi, Marina Mencinger, Kouji Izumi, Stefano Panni, Mahmut Gümüş, Mustafa Özgüroğlu, Arash Rezazadeh Kalebasty, Se Hoon Park, B. Yа. Alekseev, Fabio A. Schutz, Jian-Ri Li, Dingwei Ye, Nicholas J. Vogelzang, Sandrine Bernhard, Darren Tayama, Sanjeev Mariathasan, Almut Mecke, AnnChristine Thåström, Enrique Grande - The Lancet 2020 被引用: 787

  10. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

    著者: Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert Huddart, Earle F. Burgess, Nadine Houédé, Séverine Banek, Valentina Guadalupi, Ja Hyeon Ku, Begoña P. Valderrama, Ben Tran, Spyros Triantos, Yin Kean, Sydney Akapame, Kris Deprince, Sutapa Mukhopadhyay, Nicole L. Stone, Arlene O. Siefker‐Radtke - New England Journal of Medicine 2023 被引用: 291

  11. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  12. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    著者: Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar - The Lancet Oncology 2021 被引用: 267

  13. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

    著者: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Yen-Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross‐Goupil, Tian Zhang, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stéphane Oudard, Delphine Topart, Hans J. Hammers, Hiroshi Kitamura, David F. McDermott, Adriano da Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles - New England Journal of Medicine 2024 被引用: 285

  14. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

    著者: Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas - Journal of Clinical Oncology 2023 被引用: 211

  15. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N. Symeonides, Jaroslav Hájek, Howard Gurney, Yen‐Hwa Chang, Jae‐Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Joseph E. Burgents, Lei Xu, Kentaro Imai, David I. Quinn, Toni K. Choueiri, Piotr Tomczak, Toni K. Choueiri, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Jaroslav Hájek, Tzu-Ping Lin, Stefan N. Symeonides, Jae‐Lyun Lee, Piotr Sawrycki, Naomi B. Haas, Howard Gurney, Mauricio Mahave, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Christine Chevreau, John M. Burke, Gurjyot K. Doshi, Bohuslav Melichar, Delphine Topart, Stéphane Oudard, Evgeniy Kopyltsov, H. Hammers, David I. Quinn, Ajjai Alva, Juliana de Menezes, Adriano Gonçalves e Silva, Eric Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, B. Yа. Alekseev, Rustem Gafanov, А. А. Измайлов, Andrey Semenov, S. G. Afanasyev, Oleg Lipatov, T.B. Powles, Sandy Srinivas, David F. McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, М. I. Shkolnik, В. Б. Матвеев, P. Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter J. Boström, Brigitte Laguerre, Consuelo Buttigliero, Ugo De Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Rubén Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yañez Ruiz, Tomáš Büchler, Krista Kankaanranta, G. Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz ほか 133 名 - The Lancet Oncology 2022 被引用: 278

  16. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study

    著者: Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, Ugo De Giorgi, Tomáš Büchler, Naveen S. Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas E. Hutson, C. Alemany, Bradley A. McGregor, Thomas Powles, Viktor Grünwald, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Camillo Porta - The Lancet Oncology 2023 被引用: 163

  17. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

    著者: Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae‐Lyun Lee, Niven Mehra, Ray McDermott, Núria Sala‐González, Peter C.C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Rustem Gafanov, Maria De Santis, Eli Rosenbaum, Michael Kolinsky, Felipe Rey, Kun‐Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian Poehlein, Evan Y. Yu - Journal of Clinical Oncology 2023 被引用: 132

  18. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    著者: Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Sydney Akapame, Ademi Santiago-Walker, Manish Monga, Anne O’Hagan, Yohann Loriot, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott T. Tagawa, Aude Fléchon, B. Ya. Alexeev, Sergey Varlamov, Robert Huddart, Earle F. Burgess, Arash Rezazadeh, Arlene O. Siefker‐Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begoña Mellado, Omi Parikh, Peter Schatteman, Stéphane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio V. Scagliotti, Giovanni Schinzari, Jae‐Lyun Lee, Mikhail Shkolnik, Mark T. Fleming, Monika Joshi, Peter H. O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, R. Delva, Frédéric Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, C. Cebotaru, Ignacio Durán, Víctor Moreno, José Luis Perez‐Gracia, Álvaro Pinto, Wen-Pin Su, Shian‐Shiang Wang, John D. Hainsworth, Ian D. Schnadig, Sandhya Srinivas, Nicholas J. Vogelzang, Wolfgang Loidl, Johannes Meran, M. Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, S. Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauß, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora N. Sternberg, Sun Young Rha, Iurie Bulat, А. А. Измайлов, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, M.I. Sáez, Isabel Syndikus ほか 6 名 - The Lancet Oncology 2022 被引用: 169

  19. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

    著者: Jung Yong Hong, Ji Yeong An, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung‐Mee Kim, Won Ki Kang, Seung Tae Kim - Translational Cancer Research 2020 被引用: 93

  20. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

    著者: Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem, Kuhn‐Uk Lee, Lucjan Wyrwicz, Michael Schenker, María Alsina, Min‐Hee Ryu, Hyun Cheol Chung, Ludovic Evesque, Salah-Eddin Al-Batran, Se Hoon Park, M. Lichinitser, Narikazu Boku, Markus Moehler, Janet Hong, Hua Xiong, Roland Hallwachs, Ilaria Conti, Julien Taı̈eb - Annals of Oncology 2018 被引用: 503

  21. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

    著者: William D. Tap, Andrew J. Wagner, Patrick Schöffski, Javier Martín‐Broto, Anders Krarup‐Hansen, Kristen N. Ganjoo, Chueh‐Chuan Yen, Albiruni R. Abdul Razak, Alexander I. Spira, Akira Kawai, Axel Le Cesne, Brian A. Van Tine, Yoichi Naito, Se Hoon Park, А. А. Феденко, Zsuzsanna Pápai, Victoria Soldatenkova, Ashwin Shahir, Gary Mo, Jennifer Wright, Robin L. Jones, for the ANNOUNCE Investigators - JAMA 2020 被引用: 301

  22. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

    著者: Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G. Mortimer, Justin I. Odegaard, Elizabeth A. Harrington, Ju-Young Lee, Taehyang Lee, Sung Yong Oh, Jung-Hun Kang, Jung Hoon Kim, Youjin Kim, Jun Ho Ji, Young Saing Kim, Kyoung Eun Lee, Jinchul Kim, Tae Sung Sohn, Ji Yeong An, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Jae J. Kim, Yang Won Min, Byung‐Hoon Min, Nayoung K. D. Kim, Sally Luke, Young Hwa Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung‐Mee Kim, Won Ki Kang - Cancer Discovery 2019 被引用: 234

  23. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

    著者: Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park, Hope E. Uronis, Keun-Wook Lee, Matthew Chau Hsien Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Höchster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Johanna C. Bendell, Thierry Alcindor, Sun Jin Sym, Eun‐Kee Song, Cheng Ean Chee, Yee Chao, Sunnie S. Y. Kim, A. Craig Lockhart, Keith L. Knutson, Jennifer Yen, Aleksandra Franovic, Jeffrey L. Nordstrom, Daner Li, Jon M. Wigginton, Jan Davidson‐Moncada, Minori Koshiji Rosales, Yung‐Jue Bang - The Lancet Oncology 2020 被引用: 190

  24. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

    著者: Toni K. Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, Marine Gross‐Goupil, Alexandr Poprach, Maria De Santis, Fabio A. Schutz, Se Hoon Park, Dmitry Nosov, Camillo Porta, Jae‐Lyun Lee, Xavier García del Muro, Elisa Biscaldi, Ray Manneh Kopp, Mototsugu Oya, He Li, Aobo Wang, Rodolfo F. Perini, Donna Vickery, Laurence Albigès, Brian I. Rini - New England Journal of Medicine 2024 被引用: 142